Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

• 90% of the cases of untreated TTTS lead to loss of one or both twins.
• Despite treatment, only a 70% survival rate for both twins is assured.
• Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
• Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

Amid a red alert for a severe heatwave in the UK, the Met Office has also warned of a "pollen bomb" that could significantly affect people with hay fever.

The forecaster said there is no evidence that pollen levels are worse this year, but symptoms may feel more severe due to a combination of high pollen counts and exposure to multiple pollen types.

A 2026 Lancet Countdown in Europe study found that climate change is altering the flowering seasons of plants that release allergenic pollen.

“The combination of the fairly breezy and dry weather is going to bring a lot of pollen into the air this week and for the coming weeks,” Alastair Culham, Professor of Botany at the University of Reading, told The Independent.

“We've seen quite a mixed year so far, a very warm, dry spring which brought pollen on early, and then a series of wet weather which has allowed the grasses to grow exceptionally well. Now the weather has warmed and dried, those grasses are going into flower and the level of pollen from grass is phenomenally high,” he added.

Also read: UK Issues Red Heat-Health Alert: How to Protect Yourself From Extreme Heat

What Is Causing the Pollen Bomb?

Rising temperatures, expected to exceed 30°C on several days this week, are causing trees and grasses to release large amounts of pollen into the air.

“Hay fever symptoms usually appear when the pollen count, which is a measure of the number of grains of pollen in one cubic meter of air, exceeds 50,” the Met Office said.

The agency noted that weather conditions influence how much pollen is released and spread. Humid and windy conditions help pollen travel, while rain can clear it from the air. On sunny days, pollen levels are typically highest in the early evening.

Read To Know: No Women Aged 20-24 Died of Cervical Cancer in England Over Five Years, Thanks to HPV Vaccine

Which Areas Will Be Most Affected?

The Met Office has warned that grass pollen will remain at high levels across England and Wales, with Yorkshire, the Midlands and the North West expected to experience very high counts.

Pollen levels are forecast to be very high across England on June 24, with temperatures reaching around 38°C in some areas.

Northern Ireland and Scotland are also expected to experience medium to high pollen levels throughout the week.

Read More: WHO Sounds Alarm on Europe's Extreme Heat: Here's How Hot It Could Get Across Countries

What Is Hay Fever?

Hay fever is a common allergy that causes sneezing, coughing and itchy eyes.

According to Allergy UK, one in four adults and one in eight children suffer from allergic rhinitis, the medical term for hay fever. Research suggests the number of sufferers is increasing each year.

The Lancet study found that hay fever sufferers now experience symptoms for up to two weeks longer than they did in the 1990s due to climate change.

Symptoms of Hay Fever

• Sneezing and coughing
• Runny or blocked nose
• Itchy, red or watery eyes
• Itchy throat, mouth, nose and ears
• Loss of smell
• Pain around the forehead and sides of the head
• Headache
• Fatigue

How to Protect Yourself

According to the UK NHS, hay fever can last for weeks or months, unlike a cold, which usually resolves within one to two weeks. While there is no cure, symptoms can be managed when pollen levels are high.

Dos

• Apply petroleum jelly around your nostrils to trap pollen
• Wear wraparound sunglasses, a mask or a wide-brimmed hat outdoors
• Shower and change clothes after being outside
• Keep windows and doors closed as much as possible
• Vacuum regularly and dust with a damp cloth
• Use a pollen filter in your car and a HEPA filter in your vacuum cleaner
• Take antihistamine drops, tablets or nasal sprays

Don't

• Cut the grass or walk on the grass
• Spend excessive time outdoors
• Keep fresh flowers inside the house
• Smoke or stay around smoke
• Dry clothes outside
• Let pets indoors if possible, as they can carry pollen inside.

More than 11,000 bottles of the blood pressure medication Chlorthalidone, manufactured in India, have been recalled in the United States, according to the Food and Drug Administration (FDA). This is the second India-made blood pressure drug to be recalled in over a month.

Mumbai-based manufacturer Inventia Healthcare Limited recalled the prescription-only Chlorthalidone Tablets USP, 25 mg on June 5 due to "failed dissolution specifications." This means that the tablets may not break down correctly in the body. The drug is sold under several brand names, including Thalitone and Hygroton, and is distributed in America by New Jersey-based Rising Pharma Holdings.

What Is Chlorthalidone Used For?

Also read: Robert F. Kennedy Jr. Launches Reforms To Speed Up Early Drug Research In US

Chlorthalidone is a diuretic, or "water pill," prescribed to treat high blood pressure and fluid retention associated with conditions such as congestive heart failure, kidney disease, and liver disease.

It works by helping the kidneys eliminate excess water and salt through urine.

The FDA has not yet classified the recall or detailed the potential health consequences for patients.

What Does Dissolution Of A Drug Mean?

Dissolution refers to the process by which a tablet breaks down and releases its active ingredient into the body after it is taken.

A dissolution failure means that, during regulatory testing, the tablets did not dissolve as required. As a result, the active ingredient may not be released properly, potentially reducing the amount of medicine that reaches the bloodstream and works as intended, according to Cardiovascular Business..

Dissolution problems can arise from several factors, including poor formulation design, manufacturing process issues, low-quality raw materials, or stability issues that affect the product over time.

Which Medication Has Been Recalled?

Also read: US FDA Panel Recommends First-Ever mRNA Flu Shot For Older Adults: All About The Moderna Vaccine

According to the FDA, 11,460 bottles of Chlorthalidone are included in the recall and carry an expiration date of April 2027.

The recall affects:

• 100-tablet bottles marked with batch RISA24001
• 1,000-tablet bottles marked with batch RISB24002

Second BP Drug Recall

Read More: 4 Indian States Roll Out IV Iron Therapy To Curb Anemia In Pregnant Women: How It Works

The recall follows another FDA recall announced on May 5 involving Amlodipine and Olmesartan Medoxomil Tablets (5 mg/40 mg), another prescription blood pressure medication.

A total of 15,696 bottles were recalled due to "failed dissolution specifications: Olmesartan Medoxomil content below specifications."

The medication was also manufactured by Alkem Laboratories Ltd. in India and distributed by Ascend Laboratories, LLC, Parsippany, New Jersey. The recalled bottles carry an expiration date of October 31, 2027.

Both recalls were issued nationwide.

Previous Large-Scale Blood Pressure Drug Recall

The latest recall follows a separate large-scale blood pressure medication recall in October, when manufacturers recalled more than 500,000 bottles of Prazosin Hydrochloride due to contamination concerns.

That recall involved potential contamination with unsafe levels of a cancer-causing chemical, prompting the manufacturer to advise patients to consult their physicians or pharmacists.

The US Department of Health and Human Services (HHS), led by Robert F. Kennedy Jr., today launched a department-wide effort aimed at restoring American leadership in clinical trials and drug testing.

“Today, HHS launched a historic department-wide effort to strengthen America’s clinical research enterprise and ensure the next generation of medical breakthroughs is developed right here in the United States. Under President Trump’s leadership, we are accelerating innovation, expanding research capacity, and ensuring lifesaving discoveries are made in America,” Kennedy wrote in a post on social media platform X.

The Food and Drug Administration (FDA)-led pilot initiative, called Operation TrialBlazer comes at a time when China is gaining ground in the global biotechnology race.

Writing in a Fox News op-ed, Kennedy said, “America should continue to lead the world in clinical research and medical innovation. Instead, we are losing ground.”

He cited a recent study showing that China now conducts more early-stage clinical trials than the United States.

In 2025, Chinese companies accounted for nearly half of global pharmaceutical licensing deal activity. “Those trends should concern every American,” Kennedy said, stressing that “the future of medicine should be built in America.”

The coordinated department-wide effort aims to accelerate the development of lifesaving treatments in the United States and ensure that patients have access to some of the most innovative therapies in the world.

The initiative brings together multiple HHS divisions, including the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Advanced Research Projects Agency for Health (ARPA-H), and the Office of the Inspector General (OIG).

The effort aims to:

• Eliminate unnecessary delays
• Reduce redundant requirements
• Address regulatory ambiguity that can slow and disincentivize U.S.-based development
• Encourage the broader biomedical research ecosystem to do the same
• Foster a clinical research economy that delivers timely, safe, and effective medical products to support a healthy America

What Is Operation TrialBlazer?

According to the FDA, the initiative will help shorten development timelines by six to 12 months through a series of measures, including pairing drug developers with qualified academic centers and contract research organizations to prepare first-in-human trial applications.

The FDA has also issued draft guidance clarifying that, in many cases, one high-quality late-stage clinical trial with confirmatory evidence will generally be sufficient to provide substantial evidence of effectiveness in support of a drug approval.

Other Programs To Accelerate Drug Research In The US

Read More: Powassan Virus: Deadly Tick-Borne Disease Spreading Across The US; Here's What You Need To Know

In addition to FDA's Operation TrialBlazer, the HHS has proposed initiatives by other divisions such as:

• NIH: Expanding support for well-powered clinical trials while advancing the use of AI, human cell-based models, real-world data, and practical trial tools to speed up therapy development without compromising scientific rigor.
• NCATS: Building on work that led to the first fully personalized CRISPR-based gene-editing treatment to accelerate therapies for rare diseases.
• National Cancer Institute (NCI): Working with cancer centers and researchers to streamline trial activation and improve enrollment in cancer studies.
• Office of the National Coordinator for Health Information Technology (ONC): Exploring ways to connect patients with clinical trials through electronic health records.
• ARPA-H: Advancing programs such as THRIVE and CATALYST to use AI and machine learning to improve trial design, predict safety, optimize dosing, and test multiple therapies simultaneously.
• HHS Office of Inspector General: Seeking public feedback on potential updates to regulations affecting incentives and participation in clinical trials.